Summary List PlacementHealthcare banking has been hot in recent months, buoyed by activity from sectors like pharmaceuticals and healthcare technology. And Raymond James' top banker sees the potential to capitalize on those tailwinds. "Biotech has been on a multi-year bull market in terms of public-equity issuance as well as M&A consolidation," Jim Bunn, president of global equities and investment banking at Raymond James, told Insider in a recent interview. "There's just a tremendous amount of super interesting drug discovery, and the public investors have been interested in investing in the biotech space at a much earlier stage," Bunn said.
In this article
No tags related to this article.